Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Suppression Clear all
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

NCT00000627
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

NCT03628066
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 25, 2026, 3:20 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

NCT00726037
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ontak
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 25, 2026, 3:20 AM EDT
Recruiting No phase listed Observational

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

NCT00187512
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

NCT00543101
View directory record Official record
Conditions
HIV Infections
Interventions
Darunavir (DRV/r), continue on current dual boosted PI
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 2 Interventional

Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1

NCT04748705
View directory record Official record
Conditions
Fibromyalgia
Interventions
IMC-1, Placebo BID Tablet
Drug
Lead sponsor
Virios Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Rogers, Arkansas • Oceanside, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cranberry Ingestion and Cycling Related Immunity and Inflammation

NCT05407701
View directory record Official record
Conditions
Inflammatory Response, Metabolic Disturbance, Immune Suppression
Interventions
Cranberry Juice, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 25, 2026, 3:20 AM EDT
Completed No phase listed Observational

Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

NCT00651222
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Death
Interventions
No intervention was required
Other
Lead sponsor
Prostate Cancer Foundation of Chicago
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 25, 2026, 3:20 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

NCT07493577
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Tirofiban, Placebo
Drug
Lead sponsor
Dr David Hasan, M.D.
Other
Eligibility
18 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 3:20 AM EDT
Not listed Phase 4 Interventional

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

NCT00751153
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Atazanavir
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2008 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Not applicable Interventional

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
management of therapy complications
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

NCT00288080
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
245
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

NCT00796133
View directory record Official record
Conditions
Ovulation
Interventions
NES/E2 gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 1 Interventional

BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy

NCT00020371
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia
Interventions
BMS-247550, filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 25, 2026, 3:20 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans

NCT02472171
View directory record Official record
Conditions
Inflammation
Interventions
High saturated fat meal, placebo powder and sunflower oil, High saturated fat meal, blueberry powder and sunflower oil, High saturated fat meal, placebo powder and DHA
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 25, 2026, 3:20 AM EDT
Completed No phase listed Observational

Immune Suppression Of Infants Treated With Steroids

NCT00433940
View directory record Official record
Conditions
Hemangioma
Interventions
Prednisolone
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 25, 2026, 3:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

NCT04614974
View directory record Official record
Conditions
Laryngomalacia, Gastro Esophageal Reflux
Interventions
Famotidine, Speech Language Therapy
Drug · Other
Lead sponsor
Reema Padia
Other
Eligibility
0 Months to 6 Months
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation

NCT05308368
View directory record Official record
Conditions
Parkinson Disease, Essential Tremor
Interventions
Ultrasound Imaging, Electromyography, Inertial Measurement Units (IMU), Functional Electrical Stimulation (FES)
Device
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 25, 2026, 3:20 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

NCT01105650
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Breast Cancer
Interventions
Fludarabine, Cyclophosphamide, Cyclosporine, Natural killer cells, IL-2, Methylprednisolone, Interleukin-2
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 25, 2026, 3:20 AM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 25, 2026, 3:20 AM EDT